1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Kopran Limited

Kopran Limited

KOPRAN.NS
Kopran LimitedIN flagNational Stock Exchange of India
191.00
INR
+1.64
- -
9.22BMarket Cap
Kopran Limited
KOPRAN.NS
(National Stock Exchange of India)

Recent

price

191.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
49.88
50.93
64.07
77.55
81.92
71.58
69.66
70.45
80.63
81.02
111.32
107.03
113.7
127.49
130.49
- -
141.09
Revenue per Share
1.16
1.37
2.85
4.4
-9.84
2.59
4.6
4.74
5.55
4.86
14.24
13.77
5.65
10.57
7.99
- -
5.33
Basic EPS, GAAP
3.52
6.18
1.56
-1.64
8.81
4.26
-0.06
3.25
-1.38
3.92
8.22
-17.09
-5.61
-2.77
-3.52
- -
- -
Free Cash Flow per Basic Share
- -
0.09
- -
- -
- -
- -
- -
- -
- -
- -
1.5
1.46
3
3
3
- -
- -
Dividend per Share
12.2
-9.48
-6.64
-2.24
-12.67
-10.23
-5.18
-0.56
4.98
9.84
22.59
35.47
35.25
42.82
10.01
- -
10
Book Value per Share
20.6
22.03
24.89
29.33
24.78
25.31
28.45
32.84
37.24
41.88
54.64
93.76
87.77
97.42
102.32
- -
103.2
Tangible Book Value per Share
39
39
39
39
40
41
43
43
43
43
43
44
48
48
48
- -
48
Basic Weighted Avg Shares
1,948
1,989
2,502
3,028
3,257
2,963
3,013
3,047
3,488
3,504
4,815
4,743
5,482
6,146
6,296
6,814
6,814
Sales/Revenue/Turnover
2.92
5.02
8.6
9.83
6.88
7.93
10.02
7.81
11.58
11.06
15.23
16.18
8.26
10.01
9.1
8.87
8.87
Operating Margin (%)
116
118
125
129
96
81
83
85
87
96
102
111
127
129
156
175
175
Depreciation Expense
49
53
111
172
-391
107
199
205
240
210
616
610
272
510
386
257
257
Net Income, GAAP
- -
- -
- -
- -
- -
- -
19.58
10.48
24.13
25.68
26.07
25.37
24.49
24.56
25.79
25.1
25.1
Effective Tax Rate (%)
2.5
2.68
4.44
5.67
-12.01
3.62
6.61
6.72
6.89
6
12.8
12.87
4.97
8.29
6.12
3.78
3.78
Profit Margin (%)
432
101
299
423
118
200
432
580
729
825
1,163
2,633
2,221
2,355
2,208
1,770
1,770
Working Capital
1
646
695
632
140
177
239
213
355
318
212
188
179
166
165
139
139
LT Debt
805
860
972
1,146
985
1,048
1,247
1,447
1,685
1,897
2,450
4,262
4,392
4,912
5,183
5,303
5,303
Total Equity
- -
7.6
11.51
14.12
- -
13.95
12.64
9.79
12.65
10.7
18.29
13.98
6.72
8.41
6.77
6.69
6.69
Return on Invested Capital (%)
- -
28.06
17.42
28.58
- -
80.96
58.03
35.55
30.89
21.76
44.06
32.38
12.9
20.25
18.13
16.91
16.91
Return on Capital (%)
9.72
- -
- -
- -
- -
- -
- -
- -
- -
65.58
87.86
47.89
16.65
27.08
30.27
53.29
53.29
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
1,416
- -
1,387
LT Borrowings
152
- -
139
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
- -
48
Market Capitalization
8,415
7,270
5,218

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
4,467
- -
5,232
Cash, Cash Equivalents & STI
372
- -
73
Accounts Receivable, Net
1,616
- -
2,627
Inventories
1,736
- -
1,642
Total Current Liabilities
2,749
- -
3,462
Payables & Accruals
- -
- -
- -
ST Debt
1,416
- -
1,387
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.99%
19.33%
2.3%
Free Cash Flow
-677.17%
-99.75%
-97.79%
Net Income, GAAP
25.97%
-5.36%
-33.26%
Sales/Revenue/Turnover
9.2%
7.37%
8.23%
Total Cash Common Dividend
- -
- -
0.16%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,170
1,526
1,589
1,816
6,146
2025
1,394
1,516
1,662
1,724
6,296
2026
1,352
1,179
1,943
2,340
6,814

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.58
2.86
3.28
- -
10.57
2025
2.3
1.53
2.16
2
7.99
2026
1.54
-2.06
1.93
3.91
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3
2025
- -
- -
- -
- -
3
2026
- -
- -
- -
- -
- -
Similar Companies
PT Kalbe Farma Tbk (PTKFY)
Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ)
Lipidor AB (publ) (LIPI.ST)
Haw Par Corporation Limited (H02.SI)
Astellas Pharma Inc. (ALPMF)
Santen Pharmaceutical Co., Ltd. (SNPHF)
Business
Kopran Limited operates as an international pharmaceutical company specializing in the manufacture and marketing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). The company’s core product portfolio includes over 30 APIs across various therapeutic segments such as antibiotics (penicillins, macrolides, cephalosporins, carbapenems), antidiabetics, cardiovascular drugs, anticoagulants, neuromodulators, and oncology products. In addition, Kopran produces finished dosage forms in diverse therapeutic categories including gastroenterology, anthelmintics, central nervous system, pain management, anti-allergics, anti-asthmatics, anti-infectives, anti-protozoals, erectile dysfunction, and respiratory drugs. The company also offers contract development and manufacturing services, supporting pharmaceutical companies globally. Kopran operates two WHO GMP approved manufacturing facilities, including a wholly owned subsidiary, Kopran Research Laboratories Limited, which has notable API manufacturing units in India. Founded in 1958 and headquartered in Mumbai, India, Kopran has recently undergone significant strategic and operational developments. The company has approved a merger with a promoter group company to consolidate operations and enhance shareholding structure. In the past 1-2 years, Kopran has experienced financial challenges, including a sharp decline in revenue and profitability, with Q2 FY26 showing substantial losses and margin pressures attributed to operational inefficiencies. Despite business challenges, Kopran continues to invest in product innovation such as the development and patenting of Nitrosamine and genotoxic impurity free Nitroxoline, exemplifying its commitment to quality and innovation in APIs. The company maintains a focus on strengthening its supply chain and expanding its product offerings, aiming to stabilize revenue and regain profitability. Kopran’s business segments cover pharmaceutical formulations, API manufacturing, and contract manufacturing underpinned by advanced reaction capabilities such as chiral synthesis, high-pressure hydrogenation, enzymatic reactions, and cryogenic processes. The company targets generic drug manufacturers and pharmaceutical companies worldwide, catering to regulated markets. While facing recent financial headwinds, Kopran is positioned as a key player in the Indian pharmaceutical landscape with a strong historical presence and ongoing initiatives aimed at operational turnaround and growth. Kopran Limited trades on the National Stock Exchange of India under the ticker KOPRAN and continues to report compliance with regulatory standards including regular business responsibility and sustainability disclosures.